Efficacy of Cardioneurablation for Vasodepressor Vasovagal Syncope
Zhenhuan Chen,Ying Li,Yuan Liu,Guowang Shen,Ganwei Xiong,Bo Wu,Yanfeng Liu,Xiantao Huang,Hongyan Li,Haiwen Zhou,Zhicheng Xu,Gulao Zhang,Yu Tao,Fanzhi Zhang,Hengli Lai
DOI: https://doi.org/10.1101/2023.09.15.23295646
2023-01-01
Abstract:Objective Cardioneuroablation (CNA) is effective for cardiac inhibitory and mixed vasovagal syncope (VVS) but not vasodepressor VVS. This study aimed to assess the therapeutic benefits of CNA in vasodepressor VVS. Methods VVS patients hospitalized in the Department of Cardiology of Jiangxi Provincial People’s Hospital were retrospectively reviewed. Holter monitoring was performed before, during, and 3 months after CNA. Changes in heart rate and Wenckebach point of atrioventricular conduction before and after ablation were compared. Results Thirty-five patients were enrolled, 18 men and 17 women. Mean age was 47.48 ± 16.49 years. Median duration of syncope was 24.0 months (range, 2.5–66.0). Median number of syncope episodes before treatment was two (range, 2–4). The time domain indexes of heart rate variability, mean heart rate, maximum heart rate, and minimum heart rate were significantly higher 3 months after CNA. Mean follow-up was 11 ± 4.67 months. Recurrent syncope occurred in two patients with vasodepressor VVS, one of them with presyncope symptoms in vasodepressor type; and one patient occurred with mixed VVS, without presyncope symptoms. No serious complications occurred. CNA is safe and effective in the treatment of vasodepressor VVS. Conclusions CNA is effective for treating vasodepressor VVS. Our study provides a theoretical basis for individualization of treatment in patients with vasodepressor VVS. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial This is a retrospective study ### Funding Statement This work was supported by grants from the National Natural Science Foundation of China (82000276), Supported by Administration of Traditional Chinese Medicine of Jiangxi Province (2020A0148), Grant for Science and Technology Project of Jiangxi Provincial Health Commission (202310005). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics Committee of Jiangxi Provincial People's Hospital I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.